LIFE CooperativeLIFE Cooperative

Polyganics

Polyganics’ NEUROCAP receives FDA 510(k)

Polyganics announced it has received FDA 510 (K) clearance for NEUROCAP. This is an innovative device, designed to reduce painful neuroma formation. Thereby it facilitates
Mucosis

Mucosis Secures €3.7M from Wellcome Trust to Fund Clinical Trials of its Respiratory Syncytial Virus Vaccine in Partnership with Imperial College London

Mucosis B.V., a clinical stage biotechnology company using a proprietary technology platform to develop next-generation and needle-free human vaccines for infectious diseases, today announced that

Uncategorized

Diagnoptics age reader receives Chinese market approval

February 15th, 2016 | by LIFE Cooperative

Diagnoptics has received market approval from the Chinese Food and Drug Administration (CFDA) for the AGE Reader SU. This allows

Polyganics

Polyganics’ NEUROCAP receives FDA 510(k)

February 1st, 2016 | by LIFE Cooperative

Polyganics announced it has received FDA 510 (K) clearance for NEUROCAP. This is an innovative device, designed to reduce painful

Mucosis

Mucosis Secures €3.7M from Wellcome Trust to Fund Clinical Trials of its Respiratory Syncytial Virus Vaccine in Partnership with Imperial College London

February 1st, 2016 | by LIFE Cooperative

Mucosis B.V., a clinical stage biotechnology company using a proprietary technology platform to develop next-generation and needle-free human vaccines for

Contact